Alexandria Real Estate Equities logo

Alexandria Real Estate Equities AI Adoption Tracker

Last updated: August 9, 2026

2.6 Developing

Overview

Alexandria Real Estate Equities (ARE) stands as a pioneer and leader in life science real estate, having created this asset class in 1994[1]. The company has strategically positioned itself to support AI-enhanced laboratory-based research, recognizing that AI/ML platforms require high-quality experimental data generated in laboratories[2]. With over three decades of experience, Alexandria operates 'Megacampus' ecosystems in key innovation clusters, providing mission-critical infrastructure for biotechnology and pharmaceutical companies leveraging artificial intelligence and machine learning for drug discovery and development[2]. Despite facing industry headwinds including oversupply and funding challenges, Alexandria continues to attract AI-focused tenants like insitro, which is building a mini AI data center within one of Alexandria's South San Francisco facilities[3]. The company's approach recognizes that 'AI is powering the future of drug discovery and development,' positioning it well for the intersection of biology and technology[2].

AI Maturity Index

2.6 /5 Explorer

Evidence medium

  • Supporting AI-enhanced lab infrastructure for over a decade [corporate]

Missing Evidence

  • No dedicated AI governance structure publicly disclosed
  • Limited direct AI vendor partnerships mentioned

Evidence medium

  • Non-tech roles show 13.8% AI mentions vs 6.7% in tech roles [jobs]
  • Leadership recognizes AI as transformative for life science industry [corporate]

Missing Evidence

  • No formal AI training programs mentioned
  • Limited technical AI expertise signals

Evidence medium

  • 17% of rental revenue from AI-using pharma companies as of June 2023 [corporate]

Missing Evidence

  • No direct ROI metrics from AI initiatives
  • Limited quantified business impact data

Radar Comparison

Company Sector Avg

Peer Comparison: Alexandria Real Estate Equities vs real-estate

Based on 31 companies in sector

Dimension Alexandria Real Estate Equities Sector Avg Diff
Adoption 3.0 3.1 -0.1
Proficiency 3.0 2.9 +0.1
Impact 2.0 3.0 -1.0
Overall 2.6 3.0 -0.4

AI Hiring Signals

Alexandria Real Estate Equities Job Postings Analysis

11.4%
AI Mention Rate
44
Jobs Sampled
5
AI-Related Jobs
Medium Confidence
Data Quality

Tech vs Non-Tech AI Requirements

Tech Roles (Engineering/Data) 6.7%
Non-Tech Roles 13.8%

Non-tech AI adoption exceeds tech roles - strong org-wide AI fluency signal

Top Departments by AI Mention Rate

Product
40.0%
Finance
33.3%
HR
33.3%
Engineering/Tech
8.3%
Data/Analytics
0.0%

Analysis

Alexandria shows interesting AI hiring patterns with non-tech roles (13.8%) showing higher AI mention rates than tech roles (6.7%), suggesting AI integration across business functions. Product, Finance, and HR lead with 33-40% AI mentions, indicating strategic organizational AI adoption beyond traditional technology roles.

View Sample Job Postings (8 sources)

Key Metrics

17% of annual rental revenue from multinational pharmaceutical companies as of June 30, 2023
AI Tenant Revenue Share
Source: https://investor.are.com/news-events-and-webcasts/news/news-details/2023/Alexandria-Real-Estate-Equities-Inc.s-One-of-a-Kind-Essential-Labspace-Platform-Empowers-the-Integration-and-Enhancement-of-Biological-Discoveries-Enabled-by-AI-to-Widen-the-Opportunities-for-and-Accelerate-the-Development-of-Novel-Medicines/default.aspx
Over 100 drug and biologic submissions to FDA developed using AI and machine learning components in 2021
FDA AI Drug Submissions
Source: https://investor.are.com/news-events-and-webcasts/news/news-details/2023/Alexandria-Real-Estate-Equities-Inc.s-One-of-a-Kind-Essential-Labspace-Platform-Empowers-the-Integration-and-Enhancement-of-Biological-Discoveries-Enabled-by-AI-to-Widen-the-Opportunities-for-and-Accelerate-the-Development-of-Novel-Medicines/default.aspx
More than a petabyte of data generated weekly using AI and machine learning tools
insitro Data Generation
Source: https://investor.are.com/news-events-and-webcasts/news/news-details/2023/Alexandria-Real-Estate-Equities-Inc.s-One-of-a-Kind-Essential-Labspace-Platform-Empowers-the-Integration-and-Enhancement-of-Biological-Discoveries-Enabled-by-AI-to-Widen-the-Opportunities-for-and-Accelerate-the-Development-of-Novel-Medicines/default.aspx
4
AI Initiatives
Source: Larridin Analysis

AI Initiatives

1

Lilly Gateway Labs San Diego

September 2025

Active

Partnership with Eli Lilly to expand innovation hub in San Diego

Alexandria partnered with Eli Lilly to open Lilly Gateway Labs San Diego, powered by Alexandria, designed to empower biotechnology companies developing life-changing medicines. The facility supports companies working across AI and various therapeutic modalities.

2

insitro AI Data Center Partnership

2024

Active

Supporting tenant's construction of mini AI data center within Alexandria facility

insitro, a machine learning-powered drug discovery company and Alexandria tenant, is building a mini AI data center at 279 East Grand Avenue within Alexandria's South San Francisco mega campus. This represents the intersection of physical lab space with computational AI infrastructure.

3

insitro Lease Extension Through 2034

2024

Active

6-year early lease renewal with AI-powered drug discovery company

Alexandria announced that insitro executed a 6-year lease extension through August 31, 2034 for 143,188 RSF, highlighting the need for laboratory space to generate large datasets that power AI capabilities in drug discovery.

4

AI-Enhanced Laboratory Infrastructure

September 2023

Active

Providing specialized laboratory space for companies using AI/ML platforms in drug discovery

Alexandria has been strategically developing high-quality Labspace infrastructure for biopharmaceutical companies leveraging AI and ML platforms for over a decade. The complexity and volume of laboratory-generated data needed to train AI/ML models requires highly integrated R&D infrastructure.

Machine Learning

Frequently Asked Questions

Alexandria provides specialized laboratory infrastructure designed for AI-enhanced research, recognizing that AI/ML platforms require high-quality experimental data generated in laboratories. The company has been strategically developing Labspace facilities for companies leveraging AI and machine learning for over a decade.

The complexity and volume of laboratory-generated data needed to train AI/ML models requires highly integrated research and development infrastructure, resulting in specialized technical laboratory space requirements that Alexandria's facilities are designed to meet.

Key AI-focused tenants include insitro (ML-powered drug discovery), Eikon Therapeutics (AI-powered imaging systems), and Generate:Biomedicines (ML-powered generative biology platform). Alexandria has also invested in several of these companies through its venture arm.

Multinational pharmaceutical companies that widely deploy AI/ML throughout R&D represent 17% of Alexandria's annual rental revenue as of June 30, 2023. The company positions itself as essential infrastructure for the AI-enabled scientific era.

Through Alexandria Venture Investments, the company invests in early-stage AI/ML-powered life science companies, including Series A investments in insitro (2018) and Generate:Biomedicines. This creates a synergy between real estate and venture investment strategies.

Related Companies

About AI Tracker

AI Tracker is a research project by Larridin, the AI execution intelligence platform.

Methodology: We analyze earnings calls, press releases, partnership announcements, and product documentation. All assessments are based solely on publicly available information—no private customer data is used.

Maturity Scoring: Each dimension is rated on a 4-tier scale (Nascent → Emerging → Scaling → Leading) based on evidence from public sources. Industry averages are computed as the median across all tracked companies in the sector.

Update cadence: Every 2-3 weeks
Last updated: August 9, 2026